Adam Feuerstein

TheStreet.com Senior Columnist

Before joining TheStreet.com in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
« Back
Page 1 of 401
Article

Oculus, Bianco and Cel-Sci Oh My!: BioBuzz

By Adam Feuerstein

Some Friday Fall tidbits from the biotech stock world.

10:53AM 11/06/09

Article

Biotech Stock Mailbag: Poniard Predictions

By Adam Feuerstein

Readers chime in on Poniard Pharmaceuticals, Chelsea Therapeutics, AMAG, Cel-Sci and Dendreon.

07:00AM 11/06/09

Article

BioCryst Competition for IV Flu Drug: BioBuzz

By Adam Feuerstein

U.S. government orders IV versions of two flu drugs to treat hospitalized patients.

06:29AM 11/06/09

Article

BioCryst Winners and Losers: BioBuzz

By Adam Feuerstein

Sorting out the latest salvo in the H1N1 investor war

02:32PM 11/05/09

Article

Cel-Sci's Lawyer Speaks: BioBuzz

By Adam Feuerstein

Cel-Sci's complaint avoids the central issue about its mystery South African partner.

10:40AM 11/05/09

Article

BioCryst Ships Flu Drug to U.S. Government: BioBuzz

By Adam Feuerstein

Initial order lower than expected but priced higher

08:03AM 11/05/09

Article

Cel-Sci's South Africa Partner a Mystery

By Adam Feuerstein

Little information is available about Byron Biopharma, which was incorporated just days before its marketing deal with Cel-Sci was announced.

10:23AM 11/04/09

Article

Chelsea Just Got Riskier: BioBuzz

By Adam Feuerstein

Change sought in a phase III trial adds risk and uncertainty.

10:41AM 11/03/09

Article

Hemispherx Cops to Ampligen FDA Delay

By Adam Feuerstein

Disclosure raises questions about the veracity of CEO's past statements.

07:47AM 11/03/09

Article

Amylin Strikes First With Obesity Drug Deal: BioBuzz

By Adam Feuerstein

Japanese drugmaker Takeda licenses worldwide rights to Amylin weight-loss pipeline.

12:09PM 11/02/09

« Back
Page 1 of 401
Dow Jones S&P 500 NASDAQ 10-Year Note
10,023.42 1,069.30 2,112.44 35.03
Oil *
76.05
UP
17.46
UP
2.67
UP
7.12
DOWN
0.30
10 Yr
3.50%
SPDR Gold
107.43
+0.17%
+0.25%
+0.34%
-0.85%
Data delayed 20 minutes

Brokerage Partners